CA2838497C - Therapeutic antibodies - Google Patents

Therapeutic antibodies Download PDF

Info

Publication number
CA2838497C
CA2838497C CA2838497A CA2838497A CA2838497C CA 2838497 C CA2838497 C CA 2838497C CA 2838497 A CA2838497 A CA 2838497A CA 2838497 A CA2838497 A CA 2838497A CA 2838497 C CA2838497 C CA 2838497C
Authority
CA
Canada
Prior art keywords
antibody
seq
human
sequence
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2838497A
Other languages
English (en)
French (fr)
Other versions
CA2838497A1 (en
Inventor
Stefan Zahn
Louise Hjerrild ZEUTHEN
Anker Jon Hansen
Kristian Kjaergaard
Soren Lund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CA2838497A1 publication Critical patent/CA2838497A1/en
Application granted granted Critical
Publication of CA2838497C publication Critical patent/CA2838497C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
CA2838497A 2011-06-06 2012-06-04 Therapeutic antibodies Active CA2838497C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11168787 2011-06-06
EP11168787.7 2011-06-06
US201161505137P 2011-07-07 2011-07-07
US61/505,137 2011-07-07
EP12159172.1 2012-03-13
EP12159172 2012-03-13
PCT/EP2012/060524 WO2012168199A1 (en) 2011-06-06 2012-06-04 Therapeutic antibodies

Publications (2)

Publication Number Publication Date
CA2838497A1 CA2838497A1 (en) 2012-12-13
CA2838497C true CA2838497C (en) 2023-02-28

Family

ID=47295509

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2838497A Active CA2838497C (en) 2011-06-06 2012-06-04 Therapeutic antibodies

Country Status (16)

Country Link
US (7) US8613926B2 (ru)
EP (3) EP3424953B1 (ru)
JP (2) JP6141834B2 (ru)
KR (1) KR101978757B1 (ru)
CN (1) CN103596982B (ru)
AU (1) AU2012266487B2 (ru)
BR (1) BR112013031198B1 (ru)
CA (1) CA2838497C (ru)
DK (3) DK3424953T3 (ru)
ES (2) ES2693647T3 (ru)
IL (1) IL229254A (ru)
PL (2) PL3424953T3 (ru)
PT (1) PT3424953T (ru)
RU (1) RU2616881C2 (ru)
TW (1) TWI564305B (ru)
WO (1) WO2012168199A1 (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012168199A1 (en) * 2011-06-06 2012-12-13 Novo Nordisk A/S Therapeutic antibodies
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
CA3080200A1 (en) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anti-pd1 antibodies and their use as therapeutics and diagnostics
WO2015105522A1 (en) * 2014-01-13 2015-07-16 Forman Stephen J Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
WO2015140591A1 (en) * 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
TWI687438B (zh) 2014-07-03 2020-03-11 英屬開曼群島商百濟神州生物科技有限公司 抗ｐｄ-ｌ１抗體及其作為治療及診斷之用途
SG11201700496WA (en) 2014-07-22 2017-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
US10435470B2 (en) 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
EP3213075B1 (en) * 2014-10-31 2020-04-29 CellTrend GmbH Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor
CA3004306A1 (en) * 2015-11-04 2017-05-11 Stephen J. Forman Chimeric antigen receptors targeting her2
US20190153113A1 (en) * 2015-11-23 2019-05-23 Innate Pharma Cd39 vascular isoform targeting agents
EP4285923A3 (en) 2015-11-25 2024-03-06 Visterra, Inc. Antibody molecules to april and uses thereof
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
MX2018008939A (es) 2016-01-22 2019-08-21 Merck Sharp & Dohme Anticuerpos anti-factor de la coagulacion xi.
AR108717A1 (es) 2016-06-14 2018-09-19 Merck Sharp & Dohme Anticuerpos antifactor de la coagulación xi
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
TWI739887B (zh) 2016-08-19 2021-09-21 英屬開曼群島商百濟神州有限公司 使用包含btk抑制劑的組合產品治療癌症
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
KR102584011B1 (ko) 2017-03-16 2023-09-27 이나뜨 파르마 에스.에이. 암 치료를 위한 조성물 및 방법
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP3630833A1 (en) * 2017-05-25 2020-04-08 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
WO2019092148A1 (en) * 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
AU2019289646A1 (en) 2018-06-18 2020-11-26 Innate Pharma Compositions and methods for treating cancer
WO2020115115A1 (en) * 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules
WO2020182974A1 (en) * 2019-03-14 2020-09-17 Morphosys Ag Antibodies targeting c5ar
CA3160574A1 (en) * 2019-12-03 2021-06-10 Fubin LI Antibody fc region having enhanced binding affinty to fcyriib
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
EP4196501A1 (en) 2020-08-12 2023-06-21 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
TW202233677A (zh) 2020-11-02 2022-09-01 新加坡商蜂鳥生物科技私人有限公司 Bcma/taci抗原結合分子
EP4277931A1 (en) * 2021-01-13 2023-11-22 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
BR112023017887A2 (pt) 2021-03-12 2023-10-10 Genmab As Proteína compreendendo um primeiro polipeptídeo e um segundo polipeptídeo, anticorpo biespecífico, ácido nucleico de codificação do dito primeiro ou segundo polipeptídeo, célula hospedeira, composição farmacêutica, proteína, anticorpo biespecífico ou composição farmacêutica para uso, e, métodos de tratamento e de preparo de um anticorpo biespecífico
WO2023041745A1 (en) 2021-09-16 2023-03-23 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
WO2023046979A1 (en) 2021-09-27 2023-03-30 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
AR127298A1 (es) 2021-10-08 2024-01-10 Genmab As Anticuerpos que se unen a cd30 y cd3
KR20240123827A (ko) * 2021-12-16 2024-08-14 상하이 바오 파마슈티컬스 컴퍼니 리미티드 항면역글로불린 분해 효소에 의해 효소 절단된 Fc 변이체
WO2024008960A1 (en) 2022-07-08 2024-01-11 Agency For Science, Technology And Research Cnx antigen-binding molecules
WO2024062073A1 (en) 2022-09-22 2024-03-28 Hummingbird Bioscience Pte. Ltd. Treatment and prevention of cancer using vista antigen-binding molecules
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2024147097A1 (en) 2023-01-03 2024-07-11 Hummingbird Bioscience Pte. Ltd. Her3-binding antibody-drug conjugate
WO2024146955A1 (en) 2023-01-06 2024-07-11 Twain Therapeutics Pte. Ltd. Antigen-binding molecules
WO2024146960A1 (en) 2023-01-06 2024-07-11 Twain Therapeutics Pte. Ltd. Antigen-binding molecules

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製Ｃ５ａレセプター
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
DE69334287D1 (de) 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US20010036650A1 (en) 1994-08-16 2001-11-01 Human Genome Sciences, Inc. C5a receptor
US5861272A (en) 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗Ｃ５ａレセプター抗体、その製造法および用途
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JPH11507513A (ja) 1995-06-05 1999-07-06 インサイト・ファーマスーティカルズ・インコーポレイテッド Ｃ５ａ様７膜貫通受容体
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
CA2279344A1 (en) 1997-01-31 1998-08-06 Incyte Pharmaceuticals, Inc. Human c5a-like receptor
AU7266898A (en) 1997-04-30 1998-11-24 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
WO2002038767A2 (en) 2000-11-07 2002-05-16 Genetics Institute, Llc. G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
TWI334439B (en) * 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
ES2283594T5 (es) 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
JP4603261B2 (ja) 2001-09-27 2010-12-22 メルク・シャープ・エンド・ドーム・コーポレイション ヒト化カルシトニン遺伝子関連ペプチド受容体をコードする単離ｄｎａ分子、関連する非ヒトトランスジェニック動物及びアッセイ方法
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
WO2003062278A1 (en) 2002-01-25 2003-07-31 G2 Therapies Ltd MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2004040000A2 (en) 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
AU2002952086A0 (en) 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
AU2003298816C1 (en) * 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2004082568A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
EP1701611B1 (en) 2003-12-24 2011-05-18 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
EP1586583A3 (en) 2004-04-16 2005-11-16 Alligator Bioscience AB (publ) Compounds that block C5a complement receptor and their use in therapy
MX2007011064A (es) * 2005-03-23 2008-02-19 Genmab As Anticuerpos contra cd38 para tratamiento de mieloma multiple.
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
ZA200900954B (en) 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
WO2008022391A1 (en) 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Method for producing antibodies
WO2008030564A2 (en) 2006-09-08 2008-03-13 Verenium Corporation Aglycosylated antibodies and methods of making and using those antibodies
WO2009053368A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
EP2254911B1 (en) 2008-02-20 2015-11-25 Novo Nordisk A/S Humanized anti-c5ar antibodies
WO2009149081A1 (en) 2008-06-02 2009-12-10 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions
US20090324585A1 (en) 2008-06-12 2009-12-31 The Trustees of the Leland Standford Junior University Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
WO2010000864A1 (en) 2008-07-04 2010-01-07 Novo Nordisk A/S Method for producing monoclonal antibodies
ES2734746T3 (es) * 2008-12-22 2019-12-11 Chemocentryx Inc Antagonistas de C5aR
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
AU2011257219B2 (en) 2010-05-28 2014-12-04 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
CN103080135B (zh) * 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 能够特异性结合组织因子途径抑制剂的抗体
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
WO2012088247A2 (en) * 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
WO2012168199A1 (en) * 2011-06-06 2012-12-13 Novo Nordisk A/S Therapeutic antibodies
US20160060351A1 (en) 2013-05-08 2016-03-03 Novo Nordisk A/S Use of C5AR Antagonists

Also Published As

Publication number Publication date
JP2014523408A (ja) 2014-09-11
US20150044231A1 (en) 2015-02-12
EP3424953A1 (en) 2019-01-09
AU2012266487A1 (en) 2013-11-21
US8846045B2 (en) 2014-09-30
BR112013031198B1 (pt) 2020-10-20
DK3424953T3 (en) 2020-11-02
US20210238300A1 (en) 2021-08-05
EP3424953B1 (en) 2020-08-05
RU2616881C2 (ru) 2017-04-18
TWI564305B (zh) 2017-01-01
US8613926B2 (en) 2013-12-24
PT3424953T (pt) 2020-11-03
CN103596982B (zh) 2016-11-02
PL3424953T3 (pl) 2021-01-25
CA2838497A1 (en) 2012-12-13
AU2012266487B2 (en) 2016-12-08
RU2013155029A (ru) 2015-07-20
CN103596982A (zh) 2014-02-19
EP2718322A1 (en) 2014-04-16
US20130004514A1 (en) 2013-01-03
EP3798230B1 (en) 2022-08-03
US10882916B2 (en) 2021-01-05
KR101978757B1 (ko) 2019-05-15
BR112013031198A2 (pt) 2016-11-29
US20170073421A1 (en) 2017-03-16
IL229254A0 (en) 2014-01-30
PL2718322T3 (pl) 2019-07-31
BR112013031198A8 (pt) 2018-01-16
KR20140036261A (ko) 2014-03-25
DK3798230T3 (en) 2022-10-31
EP2718322B1 (en) 2018-08-08
EP3798230A1 (en) 2021-03-31
IL229254A (en) 2017-09-28
JP6416177B2 (ja) 2018-10-31
WO2012168199A1 (en) 2012-12-13
US20200017599A1 (en) 2020-01-16
US10323097B2 (en) 2019-06-18
DK2718322T3 (en) 2018-12-03
JP6141834B2 (ja) 2017-06-07
US20130295116A1 (en) 2013-11-07
ES2693647T3 (es) 2018-12-13
ES2929575T3 (es) 2022-11-30
JP2017081941A (ja) 2017-05-18
US20240218076A1 (en) 2024-07-04
TW201311724A (zh) 2013-03-16

Similar Documents

Publication Publication Date Title
US10882916B2 (en) Anti-C5a receptor antibodies
JP7064666B2 (ja) ＦｃγＲＩＩＡに特異的な結合分子及びその使用
US20240228649A9 (en) Crtam antibodies and methods of treating cancer
ES2831303T3 (es) Anticuerpos terapéuticos
EP4441094A1 (en) Specific antagonist anti-sirpg antibodies
MX2013013911A (es) Anticuerpos terapeuticos.
KR20100021657A (ko) 프로테아제 활성화된 수용체-１ (ｐａｒ１)의 길항제 항체

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170524

EEER Examination request

Effective date: 20170524

EEER Examination request

Effective date: 20170524

EEER Examination request

Effective date: 20170524

EEER Examination request

Effective date: 20170524